メニュー
Request a Quote
お問い合わせ
JP
Literature - Publication Review

Evaluating a novel nanoparticle platform for controlled liraglutide release in a Type II diabetes mouse model

publication-review-evaluating-a-novel-nanoparticle512x288

A large percentage of Type 2 diabetes mortality is related to cardiovascular complications. Consequently, there is a critical need for creating novel therapeutics that not only manage blood glucose levels, but also reduce the risk of developing cardiovascular diseases.

Liraglutide (Lira) is a recently approved drug used to treat Type II diabetes with excellent hypoglycemic effects while also improving cardiovascular function in patients. However its short half-life requires daily injections increasing the risk of poor patient compliance and other complications.

Read this publication review to learn how researchers used a Type II diabetes mouse model and optical imaging with the IVIS® platform to evaluate a nanoparticle system that offers a sustained and controlled release of Lira that overcomes the challenges of the short half-life of the drug.

For research use only. Not for use in diagnostic procedures. 

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Evaluating a novel nanoparticle platform for controlled liraglutide release in a Type II diabetes mouse model

Download Literature - Publication Review